16 fixed dose combination drugs, including antibiotics, banned

Now I have sufficient grounded facts (CDSCO Tier 1 + Business Standard/DrugsControl Tier 4). Writing the note.

Fixed Dose Combination (FDC) Drugs Ban — 16 FDCs (2026)

1. At a Glance

Fixed Dose Combinations (FDCs) are drugs containing two or more Active Pharmaceutical Ingredients (APIs) in a single dosage form, manufactured/distributed in a fixed ratio. [S1]
In June 2026, the Union Health Ministry banned 16 FDCs, including antibiotic, topical and cosmetic combinations, on grounds of lacking therapeutic justification and posing patient-safety risk. [S1][S3]
Relevant for UPSC as it links drug regulation, antimicrobial resistance (AMR), consumer/patient safety, and regulatory institutions (CDSCO/DTAB) — a recurring GS-II/GS-III theme.

2. Why in the News

Union Health Ministry issued a gazette notification (June 2026) prohibiting manufacture, sale and distribution of 16 named FDCs after expert review found no peer-reviewed scientific evidence supporting their rationality. [S1][S3]

3. Background & Evolution

Regulation of FDCs falls under the Drugs and Cosmetics Act, 1940 and Rules, 1945, enforced via CDSCO (Central Drugs Standard Control Organisation), under the Ministry of Health and Family Welfare. [S2]
Review of the 16 FDCs was initiated in 2021 by an expert committee, later examined by the Drug Technical Advisory Board (DTAB) and its sub-committee. [S1]
Precedent: CDSCO/Health Ministry earlier banned a list of 156 prohibited FDCs, per notification dated 02.08.2024. [S2]
Past FDC bans have faced legal challenges — e.g., ban on FDC of S(+) Etodolac + Paracetamol (notified via S.O. 4706(E), dated 07.09.2018) was later set aside by the Delhi High Court. [S2]

4. Core Static Facts

Nodal ministry: Ministry of Health and Family Welfare (MoHFW). [S1]
Regulatory/advisory bodies: CDSCO (regulator); DTAB and its sub-committee (technical review). [S1][S2]
Enabling law: Drugs and Cosmetics Act, 1940 — Section 26A empowers the Central Government to prohibit manufacture/sale/distribution of drugs in public interest. [S2]
Scope of 2026 ban: 16 FDCs — includes antibiotic combinations (e.g., Amoxicillin + Cloxacillin + Lactic Acid Bacillus + Serratiopeptidase; Cefuroxime + Serratiopeptidase) plus certain topical/cosmetic combinations. [S1]
Basis of ban: Lack of "therapeutic justification"/scientific rationality per DTAB sub-committee findings; review initiated 2021. [S1]

5. Multi-Dimensional Analysis

Scientific/Technological: Irrational drug combinations (e.g., combining antibiotics with enzymes like Serratiopeptidase) lack pharmacodynamic rationale and established clinical evidence. [S1]
Social/Health: Irrational antibiotic FDCs risk unnecessary side effects and expose patients to needless drug combinations. [S1]
Public Health/AMR: Irrational antibiotic FDCs contribute to antimicrobial resistance (AMR), flagged globally as a major health threat. [S1]
Legal/Administrative: Bans under Section 26A face judicial scrutiny; past bans (e.g., 2018 Etodolac+Paracetamol) were struck down for inadequate DTAB backing — underscoring the importance of due process before banning. [S2]
Governance: Reflects continuing government effort at drug-list rationalization, following the larger 156-FDC ban list of August 2024. [S2]

6. Recent Developments (last 12-18 months)

02.08.2024: CDSCO notification listing 156 prohibited FDCs. [S2]
June 2026: Union Health Ministry gazette notification banning 16 additional FDCs, including antibiotic and topical/cosmetic combinations, following a review initiated in 2021 and concluded by DTAB's sub-committee. [S1][S3]

7. Prelims Hooks

FDCs = drugs with two or more APIs combined in a fixed ratio in a single dosage form. [S1]
The 2026 ban covers 16 FDCs; an earlier, larger ban (2024) covered 156 FDCs. [S1][S2]
Nodal ministry for FDC bans: Ministry of Health and Family Welfare, not the Ministry of Chemicals & Fertilizers. [S1]
Technical review body: Drug Technical Advisory Board (DTAB) and its sub-committee. [S1]
Enabling legal provision: Section 26A, Drugs and Cosmetics Act, 1940. [S2]
Review of the 16 FDCs was initiated in 2021. [S1]
Example banned antibiotic FDC: Amoxicillin + Cloxacillin + Lactic Acid Bacillus + Serratiopeptidase. [S1]
Another flagged combination: Cefuroxime + Serratiopeptidase — deemed pharmacodynamically inappropriate. [S1]
A 2024 CDSCO notification (dated 02.08.2024) listed 156 prohibited FDCs. [S2]
The 2018 ban of S(+) Etodolac + Paracetamol (S.O. 4706(E)) was later set aside by the Delhi High Court. [S2]
Irrational antibiotic FDCs are linked to worsening Antimicrobial Resistance (AMR). [S1]
Regulator for drug approvals/bans in India: CDSCO, under MoHFW. [S2]

8. Mains Relevance

GS-II: Health — Government policies/interventions for issues relating to health; Regulatory bodies. Also touches Governance — transparency/accountability of regulatory decision-making.
GS-III: Science & Technology — issues relating to bio-technology/pharma; Economy — pharmaceutical industry regulation.
Plausible Mains stems: 1. "What are Fixed Dose Combination drugs? Discuss the rationale behind periodic bans on irrational FDCs in India and their implications for antimicrobial resistance." (GS-III) 2. "Examine the institutional mechanism (CDSCO, DTAB) for drug regulation in India. How effective has it been in curbing irrational drug combinations?" (GS-II) 3. "Antimicrobial resistance is a silent pandemic. Discuss the role of irrational fixed-dose antibiotic combinations in exacerbating AMR in India." (GS-III)

9. Related Topics to Study Next

Antimicrobial Resistance (AMR) & National Action Plan on AMR — directly linked to irrational antibiotic FDCs.
CDSCO and drug regulatory architecture in India — the institutional backbone of this topic.
Drugs and Cosmetics Act, 1940 & New Drugs and Clinical Trials Rules, 2019 — legal framework.
National List of Essential Medicines (NLEM) — related drug-policy tool for rational medicine use.
National Medical Commission / Pharmacy regulation — broader health regulatory ecosystem.
National Pharmaceutical Pricing Authority (NPPA) — related drug-price regulation body.
WHO Global Action Plan on AMR — international linkage (Tier 2 body: who.int).
Judicial review of executive/regulatory orders — legal angle given past court reversals of FDC bans.

10. Common Errors / Trap Areas

Confusing CDSCO (regulator) with DTAB (technical advisory body) — DTAB recommends, CDSCO/MoHFW notifies the ban.
Assuming this is India's first FDC ban — earlier bans exist, notably the 156-FDC list (2024) and the 2016 mega-ban of 344 FDCs.
Mixing up the enabling provision — it is Section 26A of the Drugs and Cosmetics Act, 1940, not a Rule under NDCT Rules 2019.
Assuming all banned FDCs are antibiotics — the 16-FDC list also includes topical/cosmetic combinations.
Believing FDC bans are final and unchallengeable — courts (e.g., Delhi HC) have previously set aside such bans on procedural grounds.

11. Sources

[S1] Government bans 16 fixed drug combinations over health safety concerns — Business Standard — https://www.business-standard.com/industry/news/centre-bans-16-fixed-drug-combinations-over-health-risks-126062000464_1.html — (tier: 4)
[S2] List of Prohibited FDC drugs (156 FDCs, dated 02.08.2024) & FDC page — CDSCO — https://cdsco.gov.in/opencms/opencms/en/Drugs/FDC/ ; https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadNewsFiles/List%20of%20Prohibited%20FDC%20drugs_%20156%20FDCs_%20dated%2002.08.2024.pdf — (tier: 1)
[S3] Ministry of Health Bans 16 Major Fixed-Dose Combination (FDC) Drugs Over Therapeutic Irrelevance and Patient Risk Factors — DrugsControl Media Services — https://drugscontrol.org/news-detail.php?newsid=45195 — (tier: 4)